Literature DB >> 2037533

Transferable resistance to extended-spectrum beta-lactams: a major threat or a minor inconvenience?

D J Payne1, S G Amyes.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2037533     DOI: 10.1093/jac/27.3.255

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  18 in total

Review 1.  More extended-spectrum beta-lactamases.

Authors:  G A Jacoby; A A Medeiros
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

2.  Extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strains causing nosocomial outbreaks of infection in the United Kingdom.

Authors:  K Shannon; P Stapleton; X Xiang; A Johnson; H Beattie; F El Bakri; B Cookson; G French
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

Review 3.  Catalytic properties of class A beta-lactamases: efficiency and diversity.

Authors:  A Matagne; J Lamotte-Brasseur; J M Frère
Journal:  Biochem J       Date:  1998-03-01       Impact factor: 3.857

Review 4.  The antimicrobial activity of cefotaxime: comparative multinational hospital isolate surveys covering 15 years.

Authors:  R N Jones
Journal:  Infection       Date:  1994       Impact factor: 3.553

Review 5.  Risk factors for acquisition of multiply drug-resistant gram-negative bacteria.

Authors:  I M Gould
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994       Impact factor: 3.267

Review 6.  Genetics of extended-spectrum beta-lactamases.

Authors:  G A Jacoby
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994       Impact factor: 3.267

7.  Patterns of antimicrobial resistance observed in Escherichia coli isolates obtained from domestic- and wild-animal fecal samples, human septage, and surface water.

Authors:  Raida S Sayah; John B Kaneene; Yvette Johnson; RoseAnn Miller
Journal:  Appl Environ Microbiol       Date:  2005-03       Impact factor: 4.792

8.  Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important beta-lactamases.

Authors:  D J Payne; R Cramp; D J Winstanley; D J Knowles
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

9.  Detection of extended-spectrum beta-lactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli.

Authors:  G A Jacoby; P Han
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

10.  Molecular epidemiology of the plasmid-encoded TEM-1 beta-lactamase in Scotland.

Authors:  C J Thomson; S G Amyes
Journal:  Epidemiol Infect       Date:  1993-02       Impact factor: 2.451

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.